Answers are grounded in this paper and cite their sources.
Background and Objective: Acute myocardial infarction (AMI) is a leading cause of morbidity and mortality worldwide, and survivors are at an increased risk of experiencing adverse left ventricular (LV) remodelling and major adverse cardiovascular events (MACE). As such, the development of non-invasive tools to predict risk following AMI remains a clinical priority. MicroRNAs (miRNAs) are small-noncoding RNAs that regulate gene expression and have come to prominence as a novel class of circulating biomarkers in AMI. In this narrative review, we summarise the current evidence that links circulating miRNAs with parameters of LV remodelling and MACE following AMI, and investigate clinical challenges that must be overcome to facilitate the translation of miRNAs into clinical use. Methods: A literature search was conducted using PubMed and Web of Science for research articles that investigated circulating miRNAs as prognostic tools following AMI, with an emphasis on articles that examined LV remodelling and MACE as clinical outcome measures. Articles written in English and published prior to April 30th 2022 were included. Key Content and Findings: A number of novel candidate miRNA biomarkers have been linked to LV remodelling and MACE following AMI. Of these miRNAs, only a handful have been successfully reproduced in independent cohorts and some, but not all, have been identified as equal or superior to current prognostic tools. Measuring miRNAs in combination has proved promising and may be a superior approach when compared to single miRNA analysis. Heterogeneous strategies to measure miRNAs in human biological samples, generally smaller sample sizes and discordance in study design and clinical endpoints are just some of the clinical challenges that must be overcome to strengthen research in this field. Conclusions: Circulating miRNAs hold promise in patient risk stratification following AMI. Future studies should utilise standardised methodologies, prioritise larger multicentre studies, incorporate miRNA panels over single miRNA analysis and should routinely compare miRNA prognosis to current clinical tools.
No takes yet. Share an insight, caveat, or question.
Brunton-O’Sullivan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: